EUCTR2012-003463-22-FR进行中（未招募）1 期
A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Relapsers to Pegylated interferon alfa/RBV
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Infection with the hepatitis C virus (HCV) with underlying mild or moderate hemophilia
- •Males 18 years of age and above
- •Have not been previously treated with an interferon
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 117
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •Not infected with the hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV)
- •Do not have a serious liver, psychiatric, blood, thyroid, lung, heart or eye disease
- •Presence of Bethesda inhibitor
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, ßS/ßC GenotypeSickle cell anaemiaMedDRA version: 21.0Level: PTClassification code: 10040641Term: Sickle cell anaemia Class: 100000004850CTIS2023-503247-34-00Vertex Pharmaceuticals Inc.14
尚未招募
3 期
ow dose gemcitabine vs standard dose gemcitabine in advanced lung cancerCTRI/2013/02/003422Tata Memorial Hospital308
招募中
3 期
A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in subjects with Transfusion-Dependent β-Thalassemia2024-516894-57-00Vertex Pharmaceuticals Inc.5
进行中（未招募）
3 期
A study to assess the safety and efficacy of a gel treatment in subjects with acne vulgarisAcne vulgarisSkin and Connective Tissue DiseasesISRCTN18067422PPM Services S.A400
招募中
3 期
Prevention of Postoperative Infections after Lung Resection with ProbioticsJPRN-jRCTs061230048Hamano Kimikazu700